2023-10-27 sec-litreleases litigation_release 64 KB 1,370 chars

SEC v. Bruce Schoengood; Medifirst Solutions, Inc.; and Joshua Tyrell, No. LR-25886, Eastern District of New York (Oct. 27, 2023) — Press Release

raw: Bruce Schoengood, Medifirst Solutions, Inc., and Joshua Tyrell

Bruce Schoengood, Medifirst Solutions, Inc., and Joshua Tyrell, No. LR-25886 (E.D.N.Y. Oct. 27, 2023)

Caption
SEC v. Bruce Schoengood, et al.
Source PDF JSON
summary

The SEC secured a final judgment against Medifirst Solutions, Inc. for a fraudulent scheme to evade federal securities registration requirements, while litigation against CEO Bruce Schoengood continues.

paragraph

The U.S. District Court for the Eastern District of New York entered a final judgment against Medifirst Solutions, Inc. for violating antifraud provisions and registration requirements. The SEC's complaint also targeted CEO Bruce Schoengood and stock promoter Joshua Tyrell for their roles in the evasion scheme. While a final judgment was entered against Tyrell in June 2022, the case against Schoengood remains pending.

narrative

The U.S. Securities and Exchange Commission filed a complaint against Medifirst Solutions, Inc., CEO Bruce Schoengood, and stock promoter Joshua Tyrell for a fraudulent scheme designed to evade federal securities registration requirements. On September 25, 2023, the court entered a final judgment against Medifirst, enjoining the company from violating Section 10(b) of the Securities Exchange Act and Section 17(a) of the Securities Act. A separate final judgment had previously been entered against Tyrell on June 16, 2022. The litigation against defendant Schoengood remains pending in the Eastern District of New York. The SEC's allegations specifically focused on the evasion of registration mandates under Section 5 of the Securities Act. No specific monetary penalties were detailed in the final judgment against the corporation.

Enriched metadata

Scheme
unregistered-securities (95%)
Court
Eastern District of New York
Entity
Medifirst Solutions, Inc.
CIK
0001522704
Classified unregistered-securities(confidence 95%). EDGAR detection: forms Form D/S-1· recall 41% / precision 30%. detection rule →
Statutes
Section 10(b) of the Securities Exchange ActSection 17(a) of the Securities ActSection 5 of the Securities ActRule 10b-5
Parties
Securities and Exchange CommissionBruce SchoengoodMedifirst Solutions, Inc.Joshua Tyrell
Keywords
medifirst solutionsmedifirstbruce schoengoodjoshua tyrellsecuritiesschoengood medifirstsecurities exchangefinal enteredagainst medifirstschoengoodsolutionsinctyrellbrucejoshua

Exhibits & Attached Documents (1)

Extracted insights

Entities 8
  • person against bruce schoengood
  • person bruce schoengood
  • person joshua tyrell
  • organization Medifirst Solutions, Inc.
  • agency Securities and Exchange Commission
  • court united states district court for the eastern district of new york
  • organization United States District Court For The Eastern District Of New York
  • organization U.S. Attorney’s Office For The Eastern District Of New York
Triples 5
  • Securities And Exchange Commission filed complaint against Medifirst Solutions, Inc., Bruce Schoengood, and Joshua Tyrell for fraudulent scheme to evade federal securities registration requirements
  • United States District Court For The Eastern District Of New York entered final judgment against Medifirst Solutions, Inc. for violating Section 10(b) of the Securities Exchange Act of 1934, Rule 10b-5, Section 17(a) of the Securities Act of 1933, and Section 5 registration requirements
  • United States District Court For The Eastern District Of New York entered final judgment against Joshua Tyrell on June 16, 2022
  • Securities And Exchange Commission maintains pending case against Bruce Schoengood
  • Securities And Exchange Commission received assistance from U.S. Attorney’s Office For The Eastern District Of New York
PDF (from attached: complaint)
SEC v. BRUCE SCHOENGOOD · Source
Text layers
Extracted body text (1,370c) 
U.S. SECURITIES AND EXCHANGE COMMISSION Litigation Release No. 25886/ October 27, 2023 Securities and Exchange Commission v. Bruce Schoengood, Medifirst Solutions, Inc., and Joshua Tyrell, No. 21-civ-00979 (E.D.N.Y., filed February 23, 2021) Final Judgment Entered Against Medifirst Solutions, Inc. On September 25, 2023, the United States District Court for the Eastern District of New York entered a final judgment against Medifirst Solutions, Inc., a Nevada corporation with its principal office in Freehold, New Jersey. The SEC’s Complaint, filed on February 23, 2021, alleged that Defendants Medifirst, Medifirst’s president and chief executive officer, Bruce Schoengood, and stock promoter Joshua Tyrell, engaged in a fraudulent scheme designed to evade registration requirements of the federal securities laws. The final judgment entered against Medifirst enjoins the company from violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and Section 17(a) of the Securities Act of 1933 and the registration requirements of Section 5 of the Securities Act. The SEC appreciates the assistance of the U.S. Attorney’s Office for the Eastern District of New York. A final judgment was entered into for Tyrell on June 16, 2022. The Commission’s case remains pending against defendant Schoengood. SEC Complaint
OCR text (1,370c · html-text · 99% conf) 
U.S. SECURITIES AND EXCHANGE COMMISSION Litigation Release No. 25886/ October 27, 2023 Securities and Exchange Commission v. Bruce Schoengood, Medifirst Solutions, Inc., and Joshua Tyrell, No. 21-civ-00979 (E.D.N.Y., filed February 23, 2021) Final Judgment Entered Against Medifirst Solutions, Inc. On September 25, 2023, the United States District Court for the Eastern District of New York entered a final judgment against Medifirst Solutions, Inc., a Nevada corporation with its principal office in Freehold, New Jersey. The SEC’s Complaint, filed on February 23, 2021, alleged that Defendants Medifirst, Medifirst’s president and chief executive officer, Bruce Schoengood, and stock promoter Joshua Tyrell, engaged in a fraudulent scheme designed to evade registration requirements of the federal securities laws. The final judgment entered against Medifirst enjoins the company from violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and Section 17(a) of the Securities Act of 1933 and the registration requirements of Section 5 of the Securities Act. The SEC appreciates the assistance of the U.S. Attorney’s Office for the Eastern District of New York. A final judgment was entered into for Tyrell on June 16, 2022. The Commission’s case remains pending against defendant Schoengood. SEC Complaint

Related documents (1)